Literature DB >> 16759796

Marked and independent prognostic significance of the CpG island methylator phenotype in neuroblastomas.

Masanobu Abe1, Frank Westermann, Akira Nakagawara, Tsuyoshi Takato, Manfred Schwab, Toshikazu Ushijima.   

Abstract

The CpG island methylator phenotype (CIMP) was closely associated with poor overall survival (OS) in Japanese neuroblastoma (NBL) cases in our previous study. Here, in German NBL cases, CIMP(+) cases (n=95) showed markedly poorer OS (hazard ratio (HR)=9.5; P<0.0001) and disease-free survival (DFS) (HR=5.4; P<0.0001) than CIMP(-) cases (n=50). All the 23 cases with N-myc amplification had CIMP. Among the remaining cases without N-myc amplification, CIMP(+) cases (n=27) had a poorer OS (HR=4.5; P=0.02) and DFS (HR=5.2; P<0.0001) than CIMP(-) cases (n=95). In multivariate analysis, CIMP and N-myc amplification had an influence on OS and DFS independent of age and disease stage. CIMP had a stronger influence on DFS than N-myc amplification while N-myc had a stronger influence on OS.

Entities:  

Mesh:

Year:  2006        PMID: 16759796     DOI: 10.1016/j.canlet.2006.05.001

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  16 in total

Review 1.  DNA methylation as a marker for the past and future.

Authors:  Toshikazu Ushijima; Takeshi Nakajima; Takao Maekita
Journal:  J Gastroenterol       Date:  2006-05       Impact factor: 7.527

Review 2.  Rethinking pheochromocytomas and paragangliomas from a genomic perspective.

Authors:  L J Castro-Vega; C Lepoutre-Lussey; A-P Gimenez-Roqueplo; J Favier
Journal:  Oncogene       Date:  2015-06-01       Impact factor: 9.867

Review 3.  Epigenetic regulation of neuroblastoma development.

Authors:  Kaat Durinck; Frank Speleman
Journal:  Cell Tissue Res       Date:  2018-01-19       Impact factor: 5.249

Review 4.  The connections between neural crest development and neuroblastoma.

Authors:  Manrong Jiang; Jennifer Stanke; Jill M Lahti
Journal:  Curr Top Dev Biol       Date:  2011       Impact factor: 4.897

5.  Phase I study of tamibarotene monotherapy in pediatric and young adult patients with recurrent/refractory solid tumors.

Authors:  Chika Nitani; Junichi Hara; Hiroshi Kawamoto; Tomoaki Taguchi; Toshimi Kimura; Kenichi Yoshimura; Akinobu Hamada; Shigehisa Kitano; Naoko Hattori; Toshikazu Ushijima; Hiromi Ono; Masako Nakamoto; Tsukiko Higuchi; Akihiro Sato
Journal:  Cancer Chemother Pharmacol       Date:  2021-04-07       Impact factor: 3.333

6.  Combination of a synthetic retinoid and a DNA demethylating agent induced differentiation of neuroblastoma through retinoic acid signal reprogramming.

Authors:  Naoko Hattori; Kiyoshi Asada; Nozomu Miyajima; Akiko Mori; Yoko Nakanishi; Kana Kimura; Mika Wakabayashi; Hideyuki Takeshima; Chika Nitani; Junichi Hara; Toshikazu Ushijima
Journal:  Br J Cancer       Date:  2021-10-11       Impact factor: 9.075

7.  Epigenetic inactivation of the Sotos overgrowth syndrome gene histone methyltransferase NSD1 in human neuroblastoma and glioma.

Authors:  María Berdasco; Santiago Ropero; Fernando Setien; Mario F Fraga; Pablo Lapunzina; Régine Losson; Miguel Alaminos; Nai-Kong Cheung; Nazneen Rahman; Manel Esteller
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-14       Impact factor: 11.205

8.  Epigenetic alterations differ in phenotypically distinct human neuroblastoma cell lines.

Authors:  Qiwei Yang; Yufeng Tian; Kelly R Ostler; Alexandre Chlenski; Lisa J Guerrero; Helen R Salwen; Lucy A Godley; Susan L Cohn
Journal:  BMC Cancer       Date:  2010-06-14       Impact factor: 4.430

9.  Clinical potentials of methylator phenotype in stage 4 high-risk neuroblastoma: an open challenge.

Authors:  Barbara Banelli; Domenico Franco Merlo; Giorgio Allemanni; Alessandra Forlani; Massimo Romani
Journal:  PLoS One       Date:  2013-05-22       Impact factor: 3.240

10.  Quantitative global and gene-specific promoter methylation in relation to biological properties of neuroblastomas.

Authors:  Nimrod B Kiss; Per Kogner; John Inge Johnsen; Tommy Martinsson; Catharina Larsson; Janos Geli
Journal:  BMC Med Genet       Date:  2012-09-17       Impact factor: 2.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.